



ASX ANNOUNCEMENT

Results of Annual General Meeting

Sydney 10 November 2021. Actinogen Medical ASX:ACW ('ACW' or 'the Company') advises that its Annual General Meeting of Shareholders was held today at 11.00 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

ENDS

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E: steven.gourlay@actinogen.com.au

Michael Roberts
Investor Relations
P: +61 2 8964 7401
E: michael.roberts@actinogen.com.au

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol. The Company is currently developing its lead compound, Xanamem[®], as a promising new therapy for Alzheimer's Disease, Fragile X Syndrome, and other potential neurological diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem[®]

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms.

The Company has studied 11 β -HSD1 inhibition by Xanamem in approximately 300 volunteers and patients, finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple indications will be conducted to further confirm and characterise Xanamem's efficacy and safety.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem[®] is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Disclosure of Proxy Votes

Actinogen Medical Limited

Annual General Meeting (AGM) 2021

Wednesday, 10 November 2021



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	394,866,647	338,614,241 85.75%	2,197,080 0.56%	2,042,001	54,055,326 13.69%	395,539,657 99.45%	2,197,080 0.55%	2,042,001
2 Re-election of Dr Geoffrey Brooke	P	458,470,947	403,730,614 88.06%	712,174 0.16%	1,800,001	54,028,159 11.78%	460,628,863 99.85%	712,174 0.15%	1,800,001
3 Approval of Employee Share Plan	P	394,759,147	318,398,574 80.66%	22,335,247 5.66%	149,501	54,025,326 13.69%	375,077,990 94.33%	22,551,247 5.67%	149,501
4 Approval of increased placement capacity	P	460,029,947	383,434,437 83.35%	22,570,184 4.91%	241,001	54,025,326 11.74%	440,113,853 95.08%	22,786,184 4.92%	241,001
5 Ratification of Prior Issue of Shares issued to Dr Steven Gourlay	P	396,750,147	320,308,436 80.73%	22,344,957 5.63%	158,501	54,096,754 13.63%	377,275,280 94.41%	22,344,957 5.59%	158,501
6 Ratification of Prior Issue of Employee Share Plan Shares issued to Employees	P	458,112,447	381,801,986 83.34%	22,208,207 4.85%	158,501	54,102,254 11.81%	438,774,330 95.18%	22,208,207 4.82%	158,501
7 Approval of Employee Share Plan Shares to Dr Geoffrey Brooke	P	396,780,147	319,566,262 80.54%	23,188,559 5.84%	128,501	54,025,326 13.62%	376,461,678 94.20%	23,188,559 5.80%	128,501



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Approval of Employee Share Plan Shares to Dr George Morstyn	P	396,780,147	320,218,436 80.70%	22,536,385 5.68%	128,501	54,025,326 13.62%	377,113,852 94.36%	22,536,385 5.64%	128,501
9 Approval of Employee Share Plan Shares to Mr Malcolm McComas	P	396,780,147	320,215,603 80.70%	22,536,385 5.68%	128,501	54,028,159 13.62%	377,113,852 94.36%	22,536,385 5.64%	128,501

